Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | NPPA | P01160 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259306 | 0.92 | PPARA (0.47) | SYKMAPTPOLBTDP1TACR1 | |
| SCHEMBL6508639 | 0.88 | ATM (0.47) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL6254719 | 0.87 | NPPA (0.52) | ATMTACR1CTSLCTSBCTSS | |
| SCHEMBL6254584 | 0.83 | NPPA (0.54) | CTSKCTSLCTSBCTSSITGB3 | |
| SCHEMBL6806843 | 0.83 | MGLL (0.43) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL30306923 | 0.83 | ATM (0.43) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL6807187 | 0.83 | PPARA (0.48) | ATMTACR1CTSKCTSLCTSB | |
| SCHEMBL28969031 | 0.82 | NPPA (0.47) | ATMTACR1CTSLCTSBCTSS | |
| SCHEMBL28968928 | 0.82 | NPPA (0.47) | ATMTACR1CTSLCTSBCTSS | |
| SCHEMBL19485480 | 0.81 | CTSK (0.62) | SYKMAPTPOLBTDP1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | SYK 4641/4885ATM 4873/4885MAPT 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.